An interventional study of Theranova 500 medium cut-off dialyzer and Hemodiafiltration in End Stage Renal Disease, sponsored by Vantive Health LLC. Completed at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.
Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2018, is one of 22 with no phase, and was the 25th registered.
2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 4 started in 2018.
This study's enrollment of 43 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 43 across the 29 interventional studies, 55 across the 4 observational. Of the 31 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Vantive Health LLC, one of the names counted as Baxter Healthcare Corporation. Under that name alone:
Vantive Health LLC is the lead sponsor of 55 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the dialyzer membrane having large enough pore sizes, larger than the conventional high-flux dialyzers. Studies have found associations between levels of large middle molecule uremic toxins and immune dysfunction and inflammation, as well as adverse outcomes. This indicates that dialysis membranes having larger pores, enabling an expanded HD (HDx) with more effective removal of large middle molecules, can have a positive impact on the inflammatory state. While data is starting to appear on the long-term use of the HDx therapy, little is still known on how large middle molecules and inflammation markers are affected over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
Device: Theranova 500 medium cut-off dialyzer
Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
Device: Hemodiafiltration
The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
Reduction ratios of lambda immunoglobulin free light chains (λ-FLC)
Time frame: Week 12
Reduction ratios of kappa immunoglobulin free light chains (k-FLC)
Time frame: Week 12
Reduction ratios of chitinase-3-like protein 1 (YKL-40)
Time frame: Week 12
Reduction ratios of fibroblast growth factor 23 (FGF-23)
Time frame: Week 12
Reduction ratios of serum beta-2 microglobulin (β2M)
Time frame: Week 12
Change from baseline in mid-week pre-dialysis serum levels of λ-FLC, κ-FLC, YKL-40, FGF-23, ß2M
Time frame: Week 12 and 24
Change from baseline in mid-week pre-dialysis serum levels of pentraxin-3 (PTX-3), high sensitivity C-reactive protein (hs-CRP), interleukin (IL-6), and interleukin-10 (IL-10)
Time frame: Week 12 and 24
Percent change from pre- to post-dialysis in mid-week serum levels of hs-CRP
Time frame: Week 12
Percent change from pre- to post-dialysis in mid-week serum levels of PTX-3
Time frame: Week 12
Percent change from pre- to post-dialysis in mid-week serum levels of IL-6
Time frame: Week 12
Percent change from pre- to post-dialysis in mid-week serum levels of IL-10
Time frame: Week 12
Change from baseline in mid-week pre-dialysis serum level of fibrinogen
Time frame: Week 12 and 24
Change from baseline in mid-week pre-dialysis serum level of albumin
Time frame: Week 12 and 24
Single pool Kt/Vurea
Time frame: Week 24
Serum phosphorous
Time frame: Week 24
Kidney Disease Quality of Life 36 (KDQOL-36)
Time frame: Baseline, Week 12, Week 24
Dialysis Symptom Index (DSI)
Time frame: Baseline, Week 12, Week 24
Serum ferritin
Time frame: Baseline, Week 12, Week 24
Transferrin Saturation (TSAT)
Time frame: Baseline, Week 12, Week 24
24-hour urine output on monthly basis
Time frame: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
Erythropoiesis stimulating agent (ESA) responsiveness
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Hemoglobin levels
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
ESA dosage by type, administration frequency, and route
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Intravenous iron dosage
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Number of adverse events of hospitalization, cardiovascular events, and infective episodes
Time frame: Week 1 through Week 24
Total patient death
Time frame: Week 1 through Week 24
Ran from Apr 2018 to primary completion in Oct 2018, 5 months.
Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 5 months is below that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.